In the face of this unprecedented pandemic, Gavi is working with countries to support COVID-19 response and to maintain and restore routine immunisation. The Alliance is also co-leading global efforts on equitable access to COVID-19 vaccines.
Respond and protect: With COVID-19 now reported in almost all Gavi-eligible countries, the Vaccine Alliance is providing immediate funding to health systems, enabling countries to protect health care workers, perform vital surveillance and training, and purchase diagnostic tests.
Maintain, restore and strengthen: Gavi will support countries to adapt and restart immunisation services, rebuild community trust and catch up those who have been missed both before and during the pandemic, while also investing in strengthening immunisation systems to be more resilient and responsive to the communities they serve.
Ensure global equitable access: Gavi is co-leading COVAX, the global effort to securing a global response to COVID-19 that is effective and fair, using its unique expertise to help identify and rapidly accelerate development, production and delivery of COVID-19 vaccines so that anyone that needs them, gets them.
Accurate, evidence-based information about COVID-19 vaccines.
Historical updates concerning the impact of and response to the COVID-19 pandemic in Gavi-supported countries.
Gavi is co-leading COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator. This involves coordinating the COVAX Facility, a global risk-sharing mechanism for pooled procurement and equitable distribution of eventual COVID-19 vaccines.
Scientists around the world are working faster than ever to develop and produce vaccines that can stop the spread of COVID-19, with 21 vaccines now being rolled out in countries worldwide. Here is an at-a-glance overview of those vaccines and…
Taking the long view on vaccine markets
Gavi’s long-term approach to developing healthy markets for critical vaccines has led to greater stability and security, providing countries with the confidence that supplies will be available to meet their demand.
2019 was a landmark year for countries co-financing their vaccine programmes
In 2019, a higher share of Gavi-supported countries than ever before met their co-financing obligations on time, thanks to strong political commitment.
Strong systems for strong vaccine coverage
In 2019, countries delivered more than 230 million routine vaccinations, a record number, supported by unprecedented levels of health system funding from Gavi to support immunisation and protect the most vulnerable children. Here is what Gavi did…
The goal of our market shaping work is to help ensure vaccine markets work better for lower-income countries. We want the maximum number of people to receive the life-saving and health-protecting benefits of immunisation.
Experimental approaches to address post-transition risks
After transitioning out of Gavi support in 2017, the Republic of Moldova is mobilising champions and advocates to strengthen vaccine confidence – which is crucial to the success and sustainability of immunisation programmes.
Typhoid: immunising against antimicrobial resistance
Typhoid fever is increasingly resistant to the main antibiotics used to treat it. Gavi is supporting a new vaccine to help control this deadly disease – and fight antimicrobial resistance.
Gavi at UNGA: Global solidarity to defeat COVID-19 and create a better world for all
September 2020 marks the 75th anniversary of the United Nations General Assembly (UNGA). This year, the focus of the high-level General Debate is the importance of effective multilateralism.
Leaders in the fight against infectious diseases
Snapshots from DRC, India and Zambia illustrate country ownership and progress in the fights against Ebola, polio and HPV.
How long after I get COVID-19 will I test negative?
Testing positive for COVID-19 – even without symptoms – can be disruptive to daily life, but how long should we expect to test positive for?
First published on 29 October 2021, updated on 13 September 2022
The COVAX Facility is seeking expressions of interest from the subject matter experts to join the COVAX Independent Product Group. The Independent Product Group (“IPG”) is established to provide scientific advice on COVID-19 vaccines and…
Q&A: Science ‘needs to listen to African voices’
Public speaking a lifelong skill for scientists. Drive behind research should come from grassroots. Science and art merge together in field of communication.
How did Kenya surpass its 2021 COVID-19 vaccination target?
Kenya was aiming to reach 10 million people with COVID-19 vaccines by the end of December 2021. Thanks to a clear strategy, COVAX support and the hard work of thousands of health workers, they reached their target.
Could mRNA vaccines protect against HIV?
Moderna has begun a trial with an experimental HIV vaccine based on the same technology underpinning its COVID-19 vaccine.
